Comparing the current results to its competitors, Universe Pharmaceuticals Inc reported Revenue increase in the 4 quarter 2025 by 0 % year on year. The revenue growth was below Universe Pharmaceuticals Inc's competitors' average revenue growth of 49.26 %, achieved in the same quarter.
Universe Pharmaceuticals Inc, slower than the average decrease reported by the company's competitors of -54.27 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -54.27 %
Universe Pharmaceuticals Inc's Comment on Competition and Industry Peers
The company operates in the Chinese patent medicine industry within the People's Republic of China, a sector characterized by significant competition and pricing pressures. Several competitors offer products at comparable or lower prices, and the market is responsive to new product introductions that can quickly gain market share. Competitors may achieve research advancements resulting in superior products, which could place the company at a competitive disadvantage. Ongoing pricing pressures, research developments, and changes in customer preferences may negatively affect the company's customer base and pricing structure.
Publicly Traded Peers of Universe Pharmaceuticals Inc
Amphastar Pharmaceuticals Inc Share Performance
+27.92%
This Quarter
Amphastar Pharmaceuticals Inc
Profile
Amphastar Pharmaceuticals Inc's business model revolves around developing, manufacturing, and marketing specialty pharmaceutical products. The company focuses on niche markets and primarily produces finished dosage form and active pharmaceutical ingredients (APIs) for injectable, inhalation, and intranasal delivery systems. Amphastar aims to provide innovative and cost-effective solutions for complex therapeutic needs, while maintaining regulatory compliance and ensuring the highest standard of quality.
Mallinckrodt Plc's business model revolves around acquiring and developing branded pharmaceutical products, as well as manufacturing and distributing generic and specialty pharmaceuticals. They aim to address unmet medical needs and improve patient lives through their diverse portfolio of drugs.
Collegium Pharmaceutical Inc's business model revolves around the development and commercialization of innovative products specifically designed to address the limitations of existing treatment options in pain management. They focus on developing extended-release formulations that offer abuse-deterrent properties to enhance patient safety and combat prescription drug abuse. By leveraging strategic partnerships, they aim to bring their products to market efficiently and effectively.
MannKind Corporation is a biopharmaceutical company that focuses on the development and commercialization of inhaled therapeutic solutions for patients with diseases such as diabetes and pulmonary arterial hypertension. The company's business model revolves around conducting research and development to create innovative inhalation therapies and gaining regulatory approvals for these treatments. They then market and distribute their products, either directly or through partnerships, to healthcare providers and patients worldwide.
Sources:
Universe Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Universe Pharmaceuticals Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
